These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. HDAC family: What are the cancer relevant targets? Witt O; Deubzer HE; Milde T; Oehme I Cancer Lett; 2009 May; 277(1):8-21. PubMed ID: 18824292 [TBL] [Abstract][Full Text] [Related]
23. Targeting histone deacetylases in neuroblastoma. Witt O; Deubzer HE; Lodrini M; Milde T; Oehme I Curr Pharm Des; 2009; 15(4):436-47. PubMed ID: 19199971 [TBL] [Abstract][Full Text] [Related]
24. The Emerging Role of HDACs: Pathology and Therapeutic Targets in Diabetes Mellitus. Dewanjee S; Vallamkondu J; Kalra RS; Chakraborty P; Gangopadhyay M; Sahu R; Medala V; John A; Reddy PH; De Feo V; Kandimalla R Cells; 2021 May; 10(6):. PubMed ID: 34071497 [TBL] [Abstract][Full Text] [Related]
25. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033 [TBL] [Abstract][Full Text] [Related]
26. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Weichert W; Röske A; Niesporek S; Noske A; Buckendahl AC; Dietel M; Gekeler V; Boehm M; Beckers T; Denkert C Clin Cancer Res; 2008 Mar; 14(6):1669-77. PubMed ID: 18347167 [TBL] [Abstract][Full Text] [Related]
27. Epigenetics in vascular disease - therapeutic potential of new agents. Xu SS; Alam S; Margariti A Curr Vasc Pharmacol; 2014 Jan; 12(1):77-86. PubMed ID: 22724461 [TBL] [Abstract][Full Text] [Related]
28. Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics. Hadnagy A; Beaulieu R; Balicki D Mol Cancer Ther; 2008 Apr; 7(4):740-8. PubMed ID: 18413789 [TBL] [Abstract][Full Text] [Related]
30. Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma. Zafar SF; Nagaraju GP; El-Rayes B Expert Opin Ther Targets; 2012 Jul; 16(7):707-18. PubMed ID: 22621256 [TBL] [Abstract][Full Text] [Related]
31. Epigenetic enzymes: A role in aging and prospects for pharmacological targeting. Pasyukova EG; Symonenko AV; Rybina OY; Vaiserman AM Ageing Res Rev; 2021 May; 67():101312. PubMed ID: 33657446 [TBL] [Abstract][Full Text] [Related]
32. Histone Deacetylase Inhibitors as Anticancer Drugs. Eckschlager T; Plch J; Stiborova M; Hrabeta J Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573 [TBL] [Abstract][Full Text] [Related]
33. Histone deacetylases as an epigenetic pillar for the development of hybrid inhibitors in cancer. Stazi G; Fioravanti R; Mai A; Mattevi A; Valente S Curr Opin Chem Biol; 2019 Jun; 50():89-100. PubMed ID: 30986654 [TBL] [Abstract][Full Text] [Related]
34. Histone deacetylases as targets for multiple diseases. Sangshetti JN; Sakle NS; Dehghan MH; Shinde DB Mini Rev Med Chem; 2013 Jun; 13(7):1005-26. PubMed ID: 22876951 [TBL] [Abstract][Full Text] [Related]
35. Therapeutic potential for HDAC inhibitors in the heart. McKinsey TA Annu Rev Pharmacol Toxicol; 2012; 52():303-19. PubMed ID: 21942627 [TBL] [Abstract][Full Text] [Related]